Pfizer PFE Paxlovid and Comirnaty — Contract with Customer, Liability, Current
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pfizer's paxlovid and comirnaty — contract with customer, liability, current.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Pfizer's paxlovid and comirnaty — contract with customer, liability, current?
- Pfizer (PFE) reported paxlovid and comirnaty — contract with customer, liability, current of $646M in Q1 2026.
- How has Pfizer's paxlovid and comirnaty — contract with customer, liability, current changed year-over-year?
- Pfizer's paxlovid and comirnaty — contract with customer, liability, current decreased by 30.7% year-over-year, from $932M to $646M.
- What does paxlovid and comirnaty — contract with customer, liability, current mean?
- This represents the portion of contract liabilities related to specific pharmaceutical products that is expected to be recognized as revenue within the next twelve months. It captures the short-term obligation to deliver goods or services to customers under existing supply contracts. Monitoring this helps analysts forecast near-term revenue realization from current order books.